SecBot SecBot
SECBOTREPLAY Home › Report › REPL

REPL · Replimune announced on August 6, 2026 that the FDA granted accelerated…

Replimune Group, Inc. · 8-K filed Aug 6, 2026 at 21:27 ET

At the news

BULLISHIMPACT 8/10

8-K filed Aug 6, 2026 at 21:27 ET

Replimune announced on August 6, 2026 that the FDA granted accelerated approval for TUDRIQEV (vusolimogene oderparepvec-wtpg) in combination with nivolumab for adults with unresectable advanced cutaneous melanoma who progressed on a PD-1-based regimen. Continued approval is contingent on verification of clinical benefit in the ongoing confirmatory Phase 3 trial IGNYTE-3. This is Replimune's first approved product, validating its RPx platform and opening a ~10,000 addressable-patient market in the U.S.

  • FDA granted accelerated approval for TUDRIQEV (RP1) + nivolumab in advanced melanoma after anti-PD-1 progression
  • IGNYTE trial (n=91 efficacy-evaluable): ORR 24.2%, median DOR 14.1 months, 86.1% of responders had DOR >6 months
  • No grade 4/5 common adverse events; most adverse reactions were grade 1-2 and transient
  • Broad label: no prior BRAF requirement, treat superficial/deep/visceral lesions, retreatment allowed

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access